Author

Peter G. Tarassoff

Observed names: P G Tarassoff, P Tarasoff, P Tarassoff, P. Tarasoff, P. Tarassoff, P.G. Tarassoff, Peter Tarasoff, Peter Tarassoff

Observed institutions: Brooke Army Medical Center, National Institutes of Health, The University of Texas MD Anderson Cancer Center, The University of Texas at San Antonio Health Science Center, Eli Lilly (United States), Walter Reed National Military Medical Center, Novartis (United States), Eisai (United States), Eisai (Japan), The University of Texas Health Science Center at Houston, Walter Reed Army Institute of Research

OpenAlex ID: A5011547686

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

1997 · H A Burris, M J Moore, et al. · Journal of Clinical Oncology · 5,897

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

1991 · J L Abbruzzese, R Grunewald, et al. · Journal of Clinical Oncology · 760

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1996 · M.L. Rothenberg, M.J. Moore, et al. · Annals of Oncology · 567

PDF

Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas

1994 · Ephraim S. Casper, Mark R. Green, et al. · Investigational New Drugs · 435

Saturation of 2?, 2?-difluorodeoxycytidine 5?-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine

1991 · Ralf Grunewald, James L. Abbruzzese, et al. · Cancer Chemotherapy and Pharmacology · 244

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.

1992 · R Grunewald, H Kantarjian, et al. · Journal of Clinical Oncology · 219

Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.

1990 · R Grunewald, H Kantarjian, et al. · PubMed · 209

Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006

2007 · Richard Weitzman, Nicholas Sauter, et al. · Critical Reviews in Oncology/Hematology · 185

Avascular necrosis of the jaws: risk factors in metastatic cancer patients

2003 · Peter Tarassoff, Katalin Csermak · Journal of Oral and Maxillofacial Surgery · 175

PDF

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial

2023 · H A Burris, M J Moore, et al. · Journal of Clinical Oncology · 167

Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC)

1994 · Y. Cormier, E. Eisenhauer, et al. · Annals of Oncology · 147

Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.

1997 · F V Fossella, S M Lippman, et al. · Journal of Clinical Oncology · 127

Difluorodeoxycytidine (dFdC) — gemcitabine: A phase I study

1992 · Elizabeth A. Poplin, Thomas Corbett, et al. · Investigational New Drugs · 75

Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days

1994 · T.J. O'Rourke, T.D. Brown, et al. · European Journal of Cancer · 46

Phase II study of gemcitabine in advanced colorectal adenocarcinoma

1992 · Dennis F. Moore, Richard Pazdur, et al. · Investigational New Drugs · 33

Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms

2003 · M.L Levitt, B Kassem, et al. · Lung Cancer · 31

950 Dyspnoea with gemcitabine is commonly seen, often disease related, transient, and rarely severe

1995 · R. Nelson, P. Tarassoff · European Journal of Cancer · 29

Phase II trial of gemcitabine in patients with advanced gastric cancer

1994 · Kathy Christman, David Kelsen, et al. · Cancer · 26

Inhibition of erythrocyte sickling in vitro by pyridoxal.

1978 · J A Kark, M P Kale, et al. · Journal of Clinical Investigation · 24

PDF

A Phase 1 Study to Assess the Absolute Bioavailability and Safety of An Oral Solution of Decitabine In Subjects with Myelodysplastic Syndromes (MDS),

2011 · Bipin Mistry, Mark M Jones, et al. · Blood · 20

Successful renal transplantation for epstein syndrome

1986 · Barbara M. Alving, Peter G. Tarassoff, et al. · American Journal of Hematology · 20

Pyridoxal phosphate as an antisickling agent in vitro.

1983 · J A Kark, P G Tarassoff, et al. · Journal of Clinical Investigation · 13

PDF

Modification of intracellular hemoglobin with pyridoxal and pyridoxal 5'-phosphate.

1982 · J A Kark, R Bongiovanni, et al. · PubMed · 8

Phase I studies of gemcitabine

1993 · FV Fossella, J Abbruzzese, et al. · European Journal of Cancer · 5

Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML)

2012 · Lia Gore, Margaret E. Macy, et al. · Blood · 2

Works count: 31

Citation count: 9,466

H-index: 20

I10-index: 22